Efficacy and safety of corticosteroids in immunocompetent patients with septic shock

doi:10.5847/wjem.j.1920-8642.2021.02.007

Abstract

Abstract:

BACKGROUND: The use of corticosteroids in septic shock has been studied for many decades but yielded conflicting results. We conducted a systematic review to evaluate the efficacy and the safety of corticosteroids in immunocompetent patients with septic shock.

METHODS: Medline via PubMed, Cochrane Central Register of Controlled Trials (CENTRAL) in the Cochrane Library, and EMBASE were searched from inception to March 2020. Two reviewers independently identified randomized controlled trials (RCTs) comparing corticosteroids with a control group for immunocompetent patients with septic shock. Data were abstracted and reported following the Cochrane Handbook for Systematic Review of Intervention and Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. The efficacy outcome included mortality and shock reversal. The safety outcomes were infection, gastrointestinal bleeding, and hyperglycemia.

RESULTS: Nine RCTs with a total of 1,298 patients were included. Compared with the control group, corticosteroid group did not lower the short-term (28 or 30 days) mortality (risk ratio [RR] 0.95, 95% confidence interval (CI) 0.85 to 1.06, inconsistency [I ²]=0%, trial sequential analysis [TSA]-adjusted CI 0.83 to 1.09, moderate-certainty evidence). Corticosteroids significantly shortened the time to shock reversal compared with the control group (mean difference [MD] -21.56 hours; 95% CI -32.95 to -10.16, I ²=0%; TSA-adjusted CI -33.33 to -9.78, moderate-certainty evidence). The corticosteroid treatment was associated with an increased risk of hyperglycemia but not the infection or gastrointestinal bleeding.

CONCLUSIONS: The corticosteroid treatment is not associated with lower short- or long- term mortality compared with placebo in immunocompetent patients with septic shock. However, corticosteroids significantly shorten the time to shock reversal without increasing the risk of infection. The patient’s immune status should also be considered during clinical treatment and clinical trials in future.

Key words: Corticosteroids, Septic shock, Immunocompetent patients, Systematic review, Meta-analysis

Xin Lu, Wei Han, Yan-xia Gao, Shi-gong Guo, Shi-yuan Yu, Xue-zhong Yu, Hua-dong Zhu, Yi Li. Efficacy and safety of corticosteroids in immunocompetent patients with septic shock[J]. World Journal of Emergency Medicine, 2021, 12(2): 124-130.

Figures/Tables 5

Figure 1.

Table 1

Characteristics of included RCTs comparing corticosteroids versus control in immunocompetent patients with septic shock

Study	Design and study place	Sample size (corticosteroids /control)	Excluded population (major selection criteria)	Intervention	Outcomes^a
Annane et al^[29] (2002)	Multicenter (19 sites), France	150/149	Advanced form of cancer or AIDS infection	IV hydrocortisone 50 mg bolus q6h and po fludrocortisone 50 μg qd versus placebo for seven days	ICU mortality, 28-day mortality, hospital mortality, one-year mortality, seven-day mortality,^b shock reversal, and safety outcomes
Briegel et al^[30] (1999)	One center, Germany	20/20	End-stage neoplasm, organ transplant recipients	IV hydrocortisone 100 mg loading, followed by 0.18 mg/(kg·h) continuous infusion until shock reversal, then reduced to 0.08 mg/(kg·h) for six days, then tapered off versus placebo (physiologic saline solution)	Shock reversal, 28-day mortality,^b ICU mortality, hospital mortality, one-year mortality, seven-day mortality,^b and safety outcomes
Cicarelli et al^[27] (2007)	One center, Brazil	14/15	Immunosuppression therapy, end stage neoplasm with a life expectancy of less than three months	IV dexamethasone 0.2 mg/kg q36h for three doses versus placebo (0.9% physiological saline solution)	Seven-day mortality, 28-day mortality, and shock reversal
Doluee et al^[32] (2018)	One center, Iran	56/52	Malignancy	IV hydrocortisone 50 mg q6h versus placebo (saline in the same volume) for seven days	Twenty-eight-day mortality
Luce et al^[31] (1988)	One center, USA	38/37	Severe immunodeficiency and AIDS	IV methylprednisolone 30 mg/kg q6h for four doses versus mannitol placebo	Incidence of ARDS, hospital mortality, and safety outcomes
Lv et al^[24] (2017)	One center, China	58/60	Immunosuppression	IV hydrocortisone 200 mg/d for six days, then tapered off versus placebo (normal saline)	Hospital mortality, 28-day mortality, shock reversal, and length of stay in ICU and hospital
Oppert et al^[28] (2005)	One center, Germany	18/23	HIV positive or recipients of organ transplants	IV hydrocortisone 50 mg bolus, followed by 0.18 mg/(kg·h) continuous infusion until shock reversal, then tapered off versus placebo	Time to cessation of vasopressor support, 28-day mortality, and shock reversal
Sprung et al^[26] (2008)	Multicenter (52 sites), Europe and Israel	251/248	Immunosuppression	IV hydrocortisone 50 mg q6h for five days, then tapered to 50 mg q12h for three days, then 50 mg QD for three days versus placebo	Mortality in ICU and hospital, 28-day mortality, one-year mortality, shock reversal, length of stay in ICU and hospital, and safety outcomes
Wan et al^[25] (2014)	One center, China	62/27	Advanced form of cancer or HIV infection	IV hydrocortisone 50 mg q6h for seven days or five days versus saline	Shock reversal, 28-day mortality, seven-day mortality, length of stay in ICU, and safety outcomes

Table 1

Figure 2.

Figure 3.

Table 2

References 36

1	Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M , et al. The third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA. 2016; 315(8):801-10. doi: 10.1001/jama.2016.0287 pmid: 26903338
2	Shankar-Hari M, Phillips GS, Levy ML, Seymour CW, Liu VX, Deutschman CS , et al. Developing a new definition and assessing new clinical criteria for septic shock: for the third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA. 2016; 315(8):775-87. doi: 10.1001/jama.2016.0289 pmid: 26903336
3	Liu SH, Liang HY, Li HY, Ding XF, Sun TW, Wang J . Effect of low high-density lipoprotein levels on mortality of septic patients: a systematic review and meta-analysis of cohort studies. World[J] Emerg Med. 2020; 11(2):109-16.
4	Wittebole X, Scicluna BP . Classification of patients with septic shock: are we there yet?[J] Crit Care. 2018; 47:320-21.
5	Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R , et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med. 2017; 43(3):304-77. doi: 10.1007/s00134-017-4683-6 pmid: 28101605
6	Vincent JL . How I treat septic shock. Intensive Care Med. 2018; 44(12):2242-4. doi: 10.1007/s00134-018-5401-8 pmid: 30315330
7	Group CS . The effectiveness of hydrocortisone in the management of severe infections. JAMA. 1963; 183:462-5. doi: 10.1001/jama.1963.63700060029012
8	Venkatesh B, Finfer S, Cohen J, Rajbhandari D, Arabi Y, Bellomo R , et al. Adjunctive glucocorticoid therapy in patients with septic shock. N Engl[J] Med. 2018; 378(9):797-808.
9	Annane D, Renault A, Brun-Buisson C, Megarbane B, Quenot JP, Siami S , et al. Hydrocortisone plus fludrocortisone for adults with septic shock. N Engl[J] Med. 2018; 378(9):809-18.
10	Zhou X, Hu C, Yao L, Fan Z, Sun L, Wang Y , et al. Effect of adjunctive corticosteroids on clinical outcomes in adult patients with septic shock: a meta-analysis of randomized controlled trials and trial sequential analysis.[J] Crit Care. 2018; 48:296-306.
11	Xu R, Wang Q, Huang Y, Wu L, Liu Q, Hu W , et al. Do low-dose corticosteroids improve survival or shock reversal from septic shock in adults? Meta-analysis with trial sequential analysis.[J] Int Med Res. 2018; 46(7):2513-24.
12	Rygard SL, Butler E, Granholm A, Moller MH, Cohen J, Finfer S , et al. Low-dose corticosteroids for adult patients with septic shock: a systematic review with meta-analysis and trial sequential analysis. Intensive Care Med. 2018; 44(7):1003-16. doi: 10.1007/s00134-018-5197-6 pmid: 29761216
13	Rochwerg B, Oczkowski SJ, Siemieniuk RAC, Agoritsas T, Belley-Cote E, D'Aragon F, et al. Corticosteroids in sepsis: an updated systematic review and meta-analysis. Crit Care Med. 2018; 46(9):1411-20. doi: 10.1097/CCM.0000000000003262 pmid: 29979221
14	Lyu QQ, Chen QH, Zheng RQ, Yu JQ, Gu XH . Effect of low-dose hydrocortisone therapy in adult patients with septic shock: a meta-analysis with trial sequential analysis of randomized controlled trials.[J] Intensive Care Med. 2020; 35(10):971-83.
15	Zhu Y, Wen Y, Jiang Q, Guo N, Cai Y, Shen X . The effectiveness and safety of corticosteroids therapy in adult critical ill patients with septic shock: a meta-analysis of randomized controlled trials. Shock. 2019; 52(2):198-207. doi: 10.1097/SHK.0000000000001202 pmid: 29889815
16	Lian XJ, Huang DZ, Cao YS, Wei YX, Lian ZZ, Qin TH , et al. Reevaluating the role of corticosteroids in septic shock: an updated meta-analysis of randomized controlled trials. Biomed Res Int. 2019; 2019:3175047. doi: 10.1155/2019/3175047 pmid: 31281831
17	Fang F, Zhang Y, Tang J, Lunsford LD, Li T, Tang R , et al. Association of corticosteroid treatment with outcomes in adult patients with sepsis: a systematic review and meta-analysis. JAMA Intern Med. 2019; 179(2):213-23. doi: 10.1001/jamainternmed.2018.5849 pmid: 30575845
18	Ni YN, Liu YM, Wang YW, Liang BM, Liang ZA . Can corticosteroids reduce the mortality of patients with severe sepsis? A systematic review and meta-analysis. Am[J] Emerg Med. 2019; 37(9):1657-64.
19	Wu J, Huang M, Wang Q, Ma Y, Jiang L . Effects and safety of separate low-dose hydrocortisone use in patients with septic shock: a meta-analysis. Hong Kong[J] Emerg Med. 2020; 27(1):39-50.
20	Annane D, Bellissant E, Bollaert PE, Briegel J, Keh D, Kupfer Y , et al. Corticosteroids for treating sepsis in children and adults. Cochrane Database Syst Rev. 2019; 12(12):CD002243.
21	Lin LL, Gu HY, Luo J, Wang L, Zhang C, Niu YM , et al. Impact and beneficial critical points of clinical outcome in corticosteroid management of adult patients with sepsis: meta-analysis and grade assessment. Front Pharmacol. 2019; 10:1101. doi: 10.3389/fphar.2019.01101 pmid: 31607929
22	Lu X, Wang X, Gao Y, Yu S, Zhao L, Zhang Z , et al. Efficacy and safety of corticosteroids for septic shock in immunocompromised patients: a cohort study from MIMIC. Am J Emerg Med. 2020; S0735- 6757(20) 30075-9.
23	Thorlund K, Engstrom J, Wetterslev J, Brok J, Imberger G. User manual for trial sequential analysis(TSA). Copenhagen Trial Unit , Centre for Clinical Intervention Research, Copenhagen, Denmark. 2011; 1-115. Available at www.ctu.dk/tsa.
24	Lv QQ, Gu XH, Chen QH, Yu JQ, Zheng RQ . Early initiation of low-dose hydrocortisone treatment for septic shock in adults: a randomized clinical trial. Am[J] Emerg Med. 2017; 35(12):1810-14.
25	Wan X, Su M, Yue J, Huang Y, Zhu W, Wan L . Clinical trial of low-dose corticosteroid treatment for surgical postoperative patients with septic shock. Journal of Kunming Medical University. 2014; 35:92-9.
26	Sprung CL, Annane D, Keh D, Moreno R, Singer M, Freivogel K , et al. Hydrocortisone therapy for patients with septic shock. N Engl[J] Med. 2008; 358(2):111-24.
27	Cicarelli DD, Vieira JE, Benseñor FE . Early dexamethasone treatment for septic shock patients: a prospective randomized clinical trial. Sao Paulo Med J. 2007; 125(4):237-41. doi: 10.1590/s1516-31802007000400009 pmid: 17992396
28	Oppert M, Schindler R, Husung C, Offermann K, Gräf KJ, Boenisch O , et al. Low-dose hydrocortisone improves shock reversal and reduces cytokine levels in early hyperdynamic septic shock. Crit Care Med. 2005; 33(11):2457-64. doi: 10.1097/01.ccm.0000186370.78639.23 pmid: 16276166
29	Annane D, Sebille V, Charpentier C, Bollaert PE, Francois B, Korach JM , et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA. 2002; 288(7):862-71. doi: 10.1001/jama.288.7.862 pmid: 12186604
30	Briegel J, Forst H, Haller M, Schelling G, Kilger E, Kuprat G , et al. Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study. Crit Care Med. 1999; 27(4):723-32. doi: 10.1097/00003246-199904000-00025 pmid: 10321661
31	Luce JM, Montgomery AB, Marks JD, Turner J, Metz CA, Murray JF . Ineffectiveness of high-dose methylprednisolone in preventing parenchymal lung injury and improving mortality in patients with septic shock. Am Rev Respir Dis. 1988; 138(1):62-8. doi: 10.1164/ajrccm/138.1.62 pmid: 3202402
32	Doluee MT, Salehi M, Gharaee AM, Jalalyazdi M, Reihani H . The effect of physiologic dose of intravenous hydrocortisone in patients with refractory septic shock: a randomized control trial. Journal of Emergency Practice and Trauma. 2018; 4(1):29-33. doi: 10.15171/jept.2017.25
33	Marik PE . The role of glucocorticoids as adjunctive treatment for sepsis in the modern era. Lancet Respir Med. 2018; 6(10):793-800. doi: 10.1016/S2213-2600(18)30265-0 pmid: 30006071
34	Skrupky LP, Kerby PW, Hotchkiss RS . Advances in the management of sepsis and the understanding of key immunologic defects. Anesthesiology. 2011; 115(6):1349-62. doi: 10.1097/ALN.0b013e31823422e8
35	Cecconi M, Evans L, Levy M, Rhodes A . Sepsis and septic shock. Lancet. 2018; 392(10141):75-87. doi: 10.1016/S0140-6736(18)30696-2 pmid: 29937192
36	MacDonald RD . Articles that may change your practice: steroids and septic shock. Air Med J. 2018; 37(6):343-4. doi: 10.1016/j.amj.2018.08.001 pmid: 30424846

Outcomes	Anticipated absolute effects ^a (95% CI)		Relative effect (95% CI)	Number of participants (studies)	Quality of the evidence (GRADE)
Outcomes	Risk with control	Risk with corticosteroids	Relative effect (95% CI)	Number of participants (studies)	Quality of the evidence (GRADE)
Short-term mortality	452 per 1,000	429 per 1,000 (384-479)	RR 0.95 (0.85-1.06)	1,298 (nine RCTs)	⊕⊕⊕? moderate^b
Long-term mortality	606 per 1,000	582 per 1,000 (528-649)	RR 0.96 (0.87-1.07)	816 (three RCTs)	⊕⊕⊕⊕ high
Seven-day mortality	412 per 1,000	280 per 1,000 (210-371)	RR 0.68 (0.51-0.90)	457 (four RCTs)	⊕⊕?? low^{b, c}
Time to shock reversal	Ranging from 75.81 to 91.2 hours	MD -21.56 (-32.95 to -10.16)		263 (four RCTs)	⊕⊕⊕? moderate^b
Shock reversal	648 per 1,000	700-1,000 (642-765)	RR 1.08 (0.99-1.18)	997 (five RCTs)	⊕⊕⊕? moderate^b
Infection	257 per 1,000	280 per 1,000 (224-352)	RR 1.09 (0.87-1.37)	894 (four RCTs)	⊕⊕⊕? moderate^c
Gastrointestinal bleeding	88 per 1,000	100 per 1,000 (69-143)	RR 1.14 (0.79-1.63)	927 (four RCTs)	⊕⊕?? low^{b, c}
Hyperglycemia	657 per 1,000	749 per 1,000 (676-834)	RR 1.14 (1.03-1.27)	539 (two RCTs)	⊕⊕⊕? moderate^b

[1]	Cheng Chi, Hao Gong, Kai Yang, Peng Peng, Xiaoxia Zhang. Early peripheral perfusion index predicts 28-day outcome in patients with septic shock [J]. World Journal of Emergency Medicine, 2024, 15(5): 372-378.
[2]	Zeyu Yang, Huiruo Liu, Dazhou Lu, Shengchuan Cao, Feng Xu, Chuanbao Li. Effects of high-dose glucose-insulin-potassium on acute coronary syndrome patients receiving reperfusion therapy: a meta-analysis [J]. World Journal of Emergency Medicine, 2024, 15(3): 181-189.
[3]	Mubing Qin, Yanxia Gao, Shigong Guo, Xin Lu, Qian Zhao, Zengzheng Ge, Huadong Zhu, Yi Li. Establishment and evaluation of animal models of sepsis-associated encephalopathy [J]. World Journal of Emergency Medicine, 2023, 14(5): 349-353.
[4]	Ralph Bou Chebl, Nadim Kattouf, Mohamad Assaf, Saadeddine Haidar, Gilbert Abou Dagher, Sarah Abdul Nabi, Rana Bachir, Mazen El Sayed. Comparing the demographic data and outcomes of septic shock patients presenting to teaching or non-teaching metropolitan hospitals in the United States [J]. World Journal of Emergency Medicine, 2022, 13(6): 433-440.
[5]	Xuan Fu, Xue Lin, Samuel Seery, Li-na Zhao, Hua-dong Zhu, Jun Xu, Xue-zhong Yu. Speckle-tracking echocardiography for detecting myocardial dysfunction in sepsis and septic shock patients: A single emergency department study [J]. World Journal of Emergency Medicine, 2022, 13(3): 175-181.
[6]	Ren-qi Yao, Chao Ren, Di Ren, Jin-xiu Li, Ying Li, Xue-yan Liu, Lei Huang, Yong Liu, Mian Peng, Yong-wen Feng, Yong-ming Yao. Development of septic shock and prognostic assessment in critically ill patients with coronavirus disease outside Wuhan, China [J]. World Journal of Emergency Medicine, 2021, 12(4): 293-298.
[7]	Yu-qing Cui, Xian-fei Ding, Huo-yan Liang, Dong Wang, Xiao-juan Zhang, Li-feng Li, Quan-cheng Kan, Le-xin Wang, Tong-wen Sun. Efficacy and safety of low-dose corticosteroids for acute respiratory distress syndrome: A systematic review and meta-analysis [J]. World Journal of Emergency Medicine, 2021, 12(3): 207-213.
[8]	Shao-hua Liu, Huo-yan Liang, Hong-yi Li, Xian-fei Ding, Tong-wen Sun, Jing Wang. Effect of low high-density lipoprotein levels on mortality of septic patients: A systematic review and meta-analysis of cohort studies [J]. World Journal of Emergency Medicine, 2020, 11(2): 109-116.
[9]	Shi-yuan Yu, Yan-xia Gao, Joseph Walline, Xin Lu, Li-na Zhao, Yuan-xu Huang, Jiang Tao, An-yong Yu, Na Ta, Ren-ju Xiao, Yi Li. Role of penehyclidine in acute organophosphorus pesticide poisoning [J]. World Journal of Emergency Medicine, 2020, 11(1): 37-47.
[10]	Yan Ma, Xiang-you Yu, Yi Wang. Dose-related effects of dexmedetomidine on immunomodulation and mortality to septic shock in rats [J]. World Journal of Emergency Medicine, 2018, 9(1): 56-63.
[11]	Gan-nan Wang, Xu-feng Chen, Li Qiao, Yong Mei, Jin-ru Lv, Xi-hua Huang, Bin Shen, Jin-song Zhang. Comparison of extracorporeal and conventional cardiopulmonary resuscitation: A meta-analysis of 2 260 patients with cardiac arrest [J]. World Journal of Emergency Medicine, 2017, 8(1): 5-11.
[12]	Li-ping Chen, Jun-hui Chen, Ying Chen, Chao Wu, Xiao-hong Yang. Efficacy and safety of glucocorticoids in the treatment of community-acquired pneumonia: A meta-analysis of randomized controlled trials [J]. World Journal of Emergency Medicine, 2015, 6(3): 172-178.
[13]	Mohsen Ebrahimi, Abbas Heydari, Reza Mazlom, Amir Mirhaghi. The reliability of the Australasian Triage Scale: a meta-analysis [J]. World Journal of Emergency Medicine, 2015, 6(2): 94-99.
[14]	Liang-shan Peng, Juan Li, Gao-sheng Zhou, Lie-hua Deng, Hua-guo Yao. Relationships between genetic polymorphisms of triggering receptor expressed on myeloid cells-1 and septic shock in a Chinese Han population [J]. World Journal of Emergency Medicine, 2015, 6(2): 123-130.
[15]	Xu-rui Luo, Hui-li Zhang, Geng-jin Chen, Wen-shu Ding, Liang Huang. Active compression-decompression cardiopulmonary resuscitation (CPR) versus standard CPR for cardiac arrest patients: a meta-analysis [J]. World Journal of Emergency Medicine, 2013, 4(4): 266-272.